Home›Stock Screener›Phaarmasia

Phaarmasia Share Price Today | Stock Price & Phaarmasia Share Screener

PHRMASI Pharmaceuticals
Live Share Price BSE
₹92.40
▲ 0.00 (0.00%)
2026-10-05 00:00:00

As of October 5, 2026, the live Phaarmasia share price (BSE: PHRMASI) is ₹92.40, unchanged from the previous close, with shares trading between ₹92.40 and ₹92.86 in today's trading session, and a 52-week range of ₹33.00–₹129.20. Check PHRMASI price range for the annual price range and momentum. Use the Phaarmasia stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Phaarmasia opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹69 and net income of ₹18, with EBITDA of ₹22, an operating margin of 2.0% and a profit margin of 26.1%.

Phaarmasia Market Cap ₹63.11 Cr.
PHRMASI P/E Ratio (TTM) 3.41
Phaarmasia P/B Ratio 2.72
EPS (TTM) ₹25.74
Dividend Yield -
Debt to Equity 0.04
PHRMASI 52 Week High ₹129.20
Phaarmasia 52 Week Low ₹33.00
Operating Margin 2.00%
Profit Margin 26.09%
PHRMASI Revenue (TTM) ₹69.00
EBITDA ₹22.00
Net Income ₹18.00
Total Assets ₹30.00
Total Equity ₹22.00

Phaarmasia Share Price Chart

Track the current stock price of Phaarmasia with an interactive chart. Analyse PHRMASI share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Phaarmasia stock quote in one place.

The quote of ₹92.40 sits between the 52-week low of ₹33.00 and the 52-week high of ₹129.20.

Phaarmasia Company Profile - Fundamental Screener

Screen Phaarmasia company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PHRMASI shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE486I01016.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E

Identifiers and Leadership

ISIN INE486I01016

Phaarmasia Balance Sheet Screener

Screen PHRMASI balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹30, up from ₹22 in 2025.

Latest statistics put total assets at ₹30 and shareholder funds at ₹22, with a leverage ratio of 0.04.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 30 22 31 28 21 22 34 33 22 20
Current Assets 27 8 18 15 8 9 20 19 8 6
Fixed Assets 1 12 13 13 13 13 13 14 14 14

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 0 0 0 0 0 0 1 1 1 1
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 22 9 10 11 12 14 13 13 12 12
Share Capital 7 7 7 7 7 7 7 7 7 7
Reserves & Surplus 15 2 4 4 5 7 7 6 5 5

Phaarmasia Income Statement Screener - Profit & Revenue Analysis

Screen Phaarmasia income statement and profit fundamentals. Analyze PHRMASI quarterly results. Phaarmasia reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For None-None, revenue was ₹69 and net profit was ₹18, equal to earnings per unit of ₹25.80, at an operating margin of 2%.

In that period expenses were ₹47, interest cost ₹0 and tax ₹4. The next period listed, 2026-March, shows revenue of ₹48 and net profit of ₹18.

Item None-None 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March 2016-March 2015-March

Revenue and Expenses

Revenue 69 48 25 31 28 18 21 25 25 21 15 22 19
Expenses 47 45 26 31 29 19 20 24 24 20 14 21 18

Operating Costs and Margins

EBITDA 22 3 -1 0 -1 -1 1 1 1 1 1 1 1
Operating Profit % 2.00% 4.00% -8.00% -3.00% -6.00% -10.00% 0.00% 3.00% 3.00% 3.00% 1.00% 1.00% 5.00%
Depreciation 0 0 0 0 0 0 0 0 1 1 0 1 1
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0

Profit and Earnings

Profit Before Tax 21 21 -2 -1 -1 -2 1 1 1 1 0 0 0
Tax 4 4 0 0 0 0 0 0 0 0 0 0 0
Net Profit 18 18 -2 -1 -1 -2 0 1 1 1 0 0 0
EPS 25.80 25.74 -2.33 -0.76 -1.84 -2.27 0.46 0.79 1.14 0.84 0.24 0.06 0.20

Phaarmasia Cash Flow Screener - Liquidity Fundamentals

Screen PHRMASI cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹22, and net cash flow was an inflow of ₹11.

Over the same period, investing activities used ₹12 and financing activities provided ₹1.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 22 -3 0 1 0 0 0 0 1 0
Investing Activities -12 0 0 0 0 0 0 0 -1 0

Financing and Net Cash

Financing Activities 1 0 0 0 0 0 0 0 0 0
Net Cash Flow 11 -3 0 1 0 0 0 0 0 0

Phaarmasia Shareholding Pattern Screener

See Phaarmasia shareholding pattern with promoter, FII, and DII holdings. Check Phaarmasia promoter holding and ownership changes for PHRMASI on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 73.51%, foreign institutions 0.00%, domestic institutions 0.06% and the public 25.66%, spread across 20,301 shareholders.

The shareholder count was 20,301 in 2026-Mar, compared with 20,286 in 2026-Jun.

Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun

Promoter Holding

Promoter Holding 73.51% 73.51% 73.51% 73.51% 73.51% 73.51% 73.51% 73.51%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.06% 0.06% 0.06% 0.06% 0.06% 0.05% 0.06% 0.06%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 25.66% 25.67% 26.18% 25.82% 25.82% 25.81% 26.17% 26.18%
Other Holding 0.76% 0.76% 0.25% 0.60% 0.61% 0.62% 0.26% 0.25%
Shareholder Count 20,301 20,286 20,620 20,512 20,497 20,404 20,682 20,642

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Phaarmasia. Phaarmasia dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Phaarmasia.

Phaarmasia Stock Index Membership - Nifty & Sensex

See which indices include Phaarmasia stock. Check PHRMASI index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Phaarmasia is not part of any tracked indices.
Only major market indices are tracked in our system.

Phaarmasia Market Events Screener - Corporate Actions

Get Phaarmasia corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Phaarmasia stock events that may affect PHRMASI share price, along with derivatives, futures and options activity and sector gainers.

11 corporate actions are listed, the most recent entry being Annual General Meeting dated September 25, 2026, with a record date of September 25, 2026.

It is followed by Quarterly Result Announcement dated August 13, 2026 and Quarterly Result Announcement dated May 29, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-09-25 2026-09-25 Annual General Meeting NA -0.33%
2026-08-13 2026-08-13 Quarterly Result Announcement NA 7.07%
2026-05-29 2026-05-29 Quarterly Result Announcement NA -4.68%
2026-02-06 2026-02-06 Quarterly Result Announcement NA -0.30%
2025-11-14 2025-11-14 Quarterly Result Announcement NA -2.94%
2025-09-25 2025-09-25 Annual General Meeting NA 23.19%
2025-08-11 2025-08-11 Quarterly Result Announcement NA 0.00%
2025-05-28 2025-05-28 Quarterly Result Announcement NA -2.44%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -4.52%
2024-11-05 2024-11-05 Quarterly Result Announcement NA 4.89%
2024-09-24 2024-09-24 Annual General Meeting NA 17.28%

Phaarmasia Competitors Screener - Peer Stocks Comparison

Screen PHRMASI competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 432,120 36.04 61,674 12.69% 11,565 36.68
Divis Laboratories 245,532 84.24 11,067 13.95% 2,568 51.70
Torrent Pharmaceuticals 181,333 84.71 13,886 20.34% 2,138 41.12
Zydus Life Science 114,284 25.27 27,658 17.64% 5,026 47.64
Cipla 108,576 32.50 29,045 2.24% 3,870 34.78
Laurus Labs 107,198 98.20 6,868 22.01% 890 58.70
Mankind Pharma 104,707 50.04 14,636 14.85% 1,938 61.75
Dr Reddys Laboratories 100,679 32.41 35,059 3.90% 4,158 53.84
Aurobindo Pharma 96,479 25.84 34,145 5.56% 3,503 50.30
Lupin 92,885 16.82 29,039 26.75% 5,356 31.59

Phaarmasia Company Announcements - News & Reports Screener

Screen PHRMASI latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated September 30, 2026.

The next most recent announcements are dated September 29, 2026 and September 26, 2026.

Date Update Actions
2026-09-30 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-29 Closure of Trading Window -
2026-09-26 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-04 Announcement Under Regulation 30_Clarification On Price Movement -
2026-09-03 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-03 Reg. 34 (1) Annual Report. -
2026-09-03 Intimation Of 45Th Annual General Meeting Of Phaarmasia Limited And Remote E-Voting. -
2026-08-31 Clarification sought from Phaarmasia Ltd -
2026-08-14 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-13 Integrated Financials For The Quarter Ended 30Th June 2026 -
2026-08-13 Financial Results For The Quarter Ended 30Th June 2026 -
2026-08-13 Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday 13Th August 2026 At 05.00 PM (IST) -
2026-08-10 Board Meeting Intimation for Meeting To Be Held On Thursday 13Th August 2026 At 05.00 PM(IST) -
2026-07-16 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-06-27 Closure of Trading Window -
2026-06-13 Clarification Sought From Phaarmasia Ltd On Price Movement -
2026-06-10 Clarification sought from Phaarmasia Ltd -
2026-06-01 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-05-29 Integrated Filing Of Financials For The Quarter And FY Ended 31St March 2026 -
2026-05-29 Financial Results For The Quarter And FY Ended 31St March 2026 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹92.40, within a 52-week range of ₹33.00 to ₹129.20. The P/E ratio is 3.41 and the P/B ratio is 2.72, with earnings per unit of ₹25.74. Market capitalisation stands at ₹63.11 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.